BiotechTube

KER-047

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Iron Deficiency Anemia

Conditions

Iron Deficiency Anemia

Trial Timeline

Nov 30, 2023 → Jan 4, 2026

NCT ID
NCT05927012

About KER-047

KER-047 is a phase 2 stage product being developed by Keros Therapeutics for Iron Deficiency Anemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05927012. Target conditions include Iron Deficiency Anemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05927012Phase 2Withdrawn

Competing Products

20 competing products in Iron Deficiency Anemia

See all competitors
ProductCompanyStageHype Score
H. pylori treatmentEisaiPhase 2/3
65
DeferasiroxNovartisPhase 3
77
CSJ137 + PlaceboNovartisPhase 1
33
Deferasirox and DeferoxamineNovartisPhase 2
52
DeferasiroxNovartisPhase 2
52
ICL670NovartisPhase 2
52
DeferasiroxNovartisApproved
85
Deferasirox + DeferasiroxNovartisPhase 2/3
65
DesferasiroxNovartisApproved
85
DeferasiroxNovartisPhase 2
52
DeferasiroxNovartisPhase 3
77
Deferasirox dispersible tablet + Defearisox film-coated tabletNovartisPhase 2
52
deferasiroxNovartisApproved
85
Deferasirox (ICL670)NovartisPhase 1/2
41
ICL670NovartisApproved
85
DeferasiroxNovartisPhase 3
77
Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + DeferoxamineNovartisPhase 2
52
DeferasiroxNovartisApproved
85
Z-213 + Saccharated Ferric OxideZeria PharmaceuticalPhase 3
76
Z-213Zeria PharmaceuticalPhase 3
76

Other Products from Keros Therapeutics

Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksPhase 2
44